FRAZER, Pa.--(EON: Enhanced Online News)--Teva Women’s Health, Inc., the maker of Plan B One-Step® (levonorgestrel) 1.5 mg tablet, announced today results of the first-ever “EC IQ” survey of 3,600 female and male undergraduate and graduate students in the United States. The Teva-sponsored survey was developed and conducted by research scientists at the Kinsey Institute, Indiana University, an institution focused on sexuality, gender and reproduction research. The survey assessed students’ contraception use and attitudes about unintended pregnancy, and revealed what demographic and lifestyle factors may contribute to their level of knowledge about over-the-counter (OTC) emergency contraception (EC), or their “EC IQ.”
“These survey findings clearly illustrate the need for more open and honest discussion about reproductive health, contraception, and OTC EC.”
The survey revealed 64 percent of 2,638 sexually active college students surveyed are using contraception inconsistently, yet only 15 percent of students sampled believe they are at high risk of an unintended pregnancy. This disconnect between contraception use and perceived risk is particularly noteworthy, given prior research shows 45 percent of all pregnancies in the U.S. are unintended (unwanted or mistimed) and 41 percent of those pregnancies are due to inconsistent use of contraception. In the survey, 69 percent of students revealed an unintended pregnancy would be highly disruptive to their lives, though many did not know some of the most basic facts about OTC EC, which helps prevent pregnancy when used as directed after unprotected sex or birth control failure. OTC EC should not be used as regular birth control because it is not as effective.
“With the unintended pregnancy rate in the U.S. remaining high and college students reporting having sex without consistent, regular contraception use, it’s important they know how OTC EC works and where to get it if they need it,” said Dr. Justin Garcia, lead researcher for the survey and renowned expert in sexual health at the Kinsey Institute, Indiana University. “These survey findings clearly illustrate the need for more open and honest discussion about reproductive health, contraception, and OTC EC.”
In the survey, EC IQ was assessed by asking 3,600 respondents a series of 12 questions on OTC EC, including what is required to purchase it in the U.S., how it works, what it is and what it is not. The survey revealed many were not well informed about OTC EC, specifically:
- 62 percent of students falsely believed there was an age restriction to purchase OTC EC.
- 53 percent were unaware an I.D. is not necessary to purchase OTC EC. In fact, OTC EC has been available in the U.S. without an age restriction or I.D. requirement since 2013.
- 57 percent of students were not aware OTC EC should be taken up to 72 hours (three days) following unprotected sex or birth control failure. The sooner it’s taken, the better it works.
After evaluating what students know about OTC EC, the survey assessed a range of lifestyle and demographic factors to investigate what may contribute to a lower or higher EC IQ. On average, the survey found students with a higher EC IQ include: women, students who think about sex often, students in committed dating relationships, students who attend private colleges, and students who identify as night owls. Conversely, students with a lower EC IQ include: men, students who have had more sexual partners in the last year, students who frequently use dating apps, students who attend single-sex colleges, and students who play varsity sports.
“At Teva Women’s Health, we are committed to educating women, and men, including college students, about their contraception options so they feel empowered to make informed decisions about their reproductive health,” said Deb Macaleer, Vice President and General Manager of Teva Women’s Health. “Working with a leading institution like the Kinsey Institute to uncover what college students know about OTC EC is a significant step in addressing education gaps to provide students with accurate information.”
About Plan B One-Step®
Plan B One-Step® (levonorgestrel) 1.5 mg tablet is a progestin-only emergency contraceptive that helps prevent pregnancy when taken within 72 hours (3 days) after birth control failure or unprotected sex. The sooner it’s taken, the better it works. Plan B One-Step® works mainly by stopping the release of an egg from the ovary. It is possible that Plan B One-Step® may also work by preventing fertilization of an egg (the uniting of sperm with the egg) or by preventing attachment (implantation) to the uterus (womb). When used as directed, about 7 out of every 8 women who would have gotten pregnant will not become pregnant after taking Plan B One-Step®. Plan B One-Step® is not an abortion pill; it will not work if a woman is already pregnant and will not affect an existing pregnancy. Plan B One-Step® is a back-up method of preventing pregnancy, and should not be used as regular birth control because it is not as effective. Side effects may include menstrual changes, nausea, lower stomach (abdominal) pain, tiredness, headache, dizziness, breast pain, and vomiting. Plan B One-Step® does not protect a woman against HIV/AIDS or sexually transmitted diseases (STDs). For additional information, visit www.PlanBOneStep.com or call the Plan B One-Step® Information Center at 800-330-1271.
Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 were $19.7 billion. For more information, visit www.tevapharm.com.
Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products; competition for our specialty products, especially Copaxone® (which faces competition from orally-administered alternatives and a generic version); our ability to integrate Allergan plc’s worldwide generic pharmaceuticals business (“Actavis Generics”) and to realize the anticipated benefits of the acquisition (and the timing of realizing such benefits); the fact that following the consummation of the Actavis Generics acquisition, we are dependent to a much larger extent than previously on our generic pharmaceutical business; potential restrictions on our ability to engage in additional transactions or incur additional indebtedness as a result of the substantial amount of debt incurred to finance the Actavis Generics acquisition; the fact that for a period of time following the Actavis Generics acquisition, we will have significantly less cash on hand than previously, which could adversely affect our ability to grow; the possibility of material fines, penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA investigations and related matters; our ability to achieve expected results from investments in our pipeline of specialty and other products; our ability to identify and successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; the extent to which any manufacturing or quality control problems damage our reputation for quality production and require costly remediation; increased government scrutiny in both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations and restrictions as well as credit risks; the effectiveness of our patents, confidentiality agreements and other measures to protect the intellectual property rights of our specialty medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing, reimbursement and coverage; competition for our generic products, both from other pharmaceutical companies and as a result of increased governmental pricing pressures; governmental investigations into sales and marketing practices, particularly for our specialty pharmaceutical products; adverse effects of political or economic instability, major hostilities or acts of terrorism on our significant worldwide operations; interruptions in our supply chain or problems with internal or third-party information technology systems that adversely affect our complex manufacturing processes; significant disruptions of our information technology systems or breaches of our data security; competition for our specialty pharmaceutical businesses from companies with greater resources and capabilities; the impact of continuing consolidation of our distributors and customers; decreased opportunities to obtain U.S. market exclusivity for significant new generic products; potential liability in the U.S., Europe and other markets for sales of generic products prior to a final resolution of outstanding patent litigation; our potential exposure to product liability claims that are not covered by insurance; any failure to recruit or retain key personnel, or to attract additional executive and managerial talent; any failures to comply with complex Medicare and Medicaid reporting and payment obligations; significant impairment charges relating to intangible assets, goodwill and property, plant and equipment; the effects of increased leverage and our resulting reliance on access to the capital markets; potentially significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner; environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2015 and in our other filings with the U.S. Securities and Exchange Commission (the "SEC"). Forward-looking statements speak only as of the date on which they are made and we assume no obligation to update or revise any forward-looking statements or other information, whether as a result of new information, future events or otherwise.